CA2540986A1 - Utilisation therapeutique du facteur xi - Google Patents

Utilisation therapeutique du facteur xi Download PDF

Info

Publication number
CA2540986A1
CA2540986A1 CA002540986A CA2540986A CA2540986A1 CA 2540986 A1 CA2540986 A1 CA 2540986A1 CA 002540986 A CA002540986 A CA 002540986A CA 2540986 A CA2540986 A CA 2540986A CA 2540986 A1 CA2540986 A1 CA 2540986A1
Authority
CA
Canada
Prior art keywords
fxi
polypeptide
patient
factor
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002540986A
Other languages
English (en)
Inventor
Rasmus Roejkjaer
Dorthe Viuff
Soeren Oestergaard
Simon Bjerregaard Jensen
Jens Jacob Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk Health Care AG
Original Assignee
Novo Nordisk Health Care Ag
Rasmus Roejkjaer
Dorthe Viuff
Soeren Oestergaard
Simon Bjerregaard Jensen
Jens Jacob Hansen
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Health Care Ag, Rasmus Roejkjaer, Dorthe Viuff, Soeren Oestergaard, Simon Bjerregaard Jensen, Jens Jacob Hansen, Novo Nordisk A/S filed Critical Novo Nordisk Health Care Ag
Publication of CA2540986A1 publication Critical patent/CA2540986A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21027—Coagulation factor XIa (3.4.21.27)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002540986A 2003-11-20 2004-11-22 Utilisation therapeutique du facteur xi Abandoned CA2540986A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200301721 2003-11-20
DKPA200301721 2003-11-20
DKPA200401141 2004-07-23
DKPA200401141 2004-07-23
PCT/DK2004/000810 WO2005049070A1 (fr) 2003-11-20 2004-11-22 Utilisation therapeutique du facteur xi

Publications (1)

Publication Number Publication Date
CA2540986A1 true CA2540986A1 (fr) 2005-06-02

Family

ID=34621448

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002540986A Abandoned CA2540986A1 (fr) 2003-11-20 2004-11-22 Utilisation therapeutique du facteur xi

Country Status (9)

Country Link
EP (1) EP1687020A1 (fr)
JP (1) JP2007513881A (fr)
KR (1) KR20060118486A (fr)
AU (1) AU2004290869A1 (fr)
BR (1) BRPI0416461A (fr)
CA (1) CA2540986A1 (fr)
RU (1) RU2006115783A (fr)
TW (1) TW200529870A (fr)
WO (1) WO2005049070A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006008266A2 (fr) * 2004-07-23 2006-01-26 Novo Nordisk Health Care Ag Proteines de liaison au facteur xi
WO2006128497A1 (fr) * 2005-06-01 2006-12-07 Novo Nordisk A/S Formule pharmaceutique de facteur xi
NZ607892A (en) 2008-12-19 2014-11-28 Baxter Int Tfpi inhibitors and methods of use
EP2305289A1 (fr) * 2009-09-16 2011-04-06 Bio-Products & Bio-Engineering Aktiengesellschaft Produits médicinaux pour le traitement de troubles de la coagulation sanguine
EP2547355B1 (fr) 2010-03-19 2017-01-11 Baxalta GmbH Inhibiteurs de tfpi et procédés d'utilisation associés
NZ629130A (en) 2012-03-21 2016-10-28 Baxalta Inc Tfpi inhibitors and methods of use
DE102012022233A1 (de) 2012-11-14 2014-05-15 Instraction Gmbh Verfahren zur Reinigung eines (Blut)plasmaproteins
DE102012022234A1 (de) 2012-11-14 2014-05-15 Instraction Gmbh Einstufiges Verfahren zur Reinigung von (Blut)Plasmaproteinen wie Albumin aus Gemischen
KR20210151949A (ko) 2020-04-05 2021-12-14 화이자 인코포레이티드 Covid-19의 치료를 위한 화합물 및 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676231A1 (fr) * 1991-05-07 1992-11-13 Aetsrn Concentre de facteur xi de la coagulation sanguine a haute activite specifique, approprie a usage therapeutique et son procede de preparation.
CA2401552A1 (fr) * 2000-03-03 2001-09-15 Curagen Corporation Nouvelles proteines et acides nucleiques codant lesdites proteines
AU2002354846B2 (en) * 2001-07-20 2007-08-02 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides

Also Published As

Publication number Publication date
AU2004290869A1 (en) 2005-06-02
BRPI0416461A (pt) 2007-03-06
TW200529870A (en) 2005-09-16
KR20060118486A (ko) 2006-11-23
EP1687020A1 (fr) 2006-08-09
JP2007513881A (ja) 2007-05-31
WO2005049070A1 (fr) 2005-06-02
RU2006115783A (ru) 2007-12-27

Similar Documents

Publication Publication Date Title
US20050181978A1 (en) Therapeutic use of factor XI
JP5037331B2 (ja) 出血性障害の処置のための第ｉｘａ因子
JP6029826B2 (ja) 補因子の非存在下において凝固活性を有する第ｉｘ因子変異体および出血性疾患の処置のためのその使用
WO2006128497A1 (fr) Formule pharmaceutique de facteur xi
JP2011517951A (ja) 修飾された第ｉｘ因子ポリペプチドおよびそれらの使用
US8697844B2 (en) Method of purifying pegylated proteins
US8383776B2 (en) Purification of factor XIII polypeptides from biological materials
JP7273918B2 (ja) 第ｘａ因子誘導体の調製
EP1651252B1 (fr) Variants de proteine c activee avec activite cytoprotectrice normale mais avec activite anticoagulante reduite
ES2481420T3 (es) Variantes de proteína C activada con actividad citoprotectora pero con actividad anticoagulante reducida
CA2540986A1 (fr) Utilisation therapeutique du facteur xi
AU2008341008A1 (en) Haemostasis- modulating compositions and uses therefor
JP5236952B2 (ja) 改善された特性を有するｆｘｉｉｉバリアント
EP2948168B1 (fr) Inhibition d'inhibiteur de la voie du facteur tissulaire a l'aide de derives de facteur xa
JP2016536368A (ja) 第Ｘａ因子の半減期を延ばす組成物および方法
MXPA06005477A (en) Therapeutic use of factor xi
KR20110017359A (ko) 폴리펩티드 변형 반응의 제어 방법
Wu Characterization of TAFI activation by the thrombin-thrombomodulin complex
KR20180089439A (ko) 재조합 세린 프로테아제
WO2009123573A1 (fr) Anticoagulants dérivés de venin de serpent naja nigricollis

Legal Events

Date Code Title Description
FZDE Discontinued